Endothelin receptor type B gene promoter hypermethylation in salivary rinses is independently associated with risk of oral cavity cancer and premalignancy.
Endothelin receptor type B (EDNRB) and kinesin family member 1A (KIF1A) are candidate tumor suppressor genes that are inactivated in cancers. In this study, we evaluated the promoter hypermethylation of EDNRB and KIF1A and their potential use for risk classification in prospectively collected salivary rinses from patients with premalignant/malignant oral cavity lesions. Quantitative methylation-specific PCR was performed to analyze the methylation status of EDNRB and KIF1A in salivary rinses of 191 patients. We proceeded to determine the association of methylation status with histologic diagnosis and estimate classification accuracy. On univariate analysis, diagnosis of dysplasia/cancer was associated with age and KIF1A or EDNRB methylation. Methylation of EDNRB highly correlated with that of KIF1A (P < 0.0001). On multivariable modeling, histologic diagnosis was independently associated with EDNRB (P = 0.0003) or KIF1A (P = 0.027) methylation. A subset of patients analyzed (n = 161) without prior biopsy-proven malignancy received clinical risk classification based on examination. On univariate analysis, EDNRB and risk classification were associated with diagnosis of dysplasia/cancer and remained significant on multivariate analysis (EDNRB: P = 0.047, risk classification: P = 0.008). Clinical risk classification identified dysplasia/cancer with a sensitivity of 71% and a specificity of 58%. The sensitivity of clinical risk classification combined with EDNRB methylation improved to 75%. EDNRB methylation in salivary rinses was independently associated with histologic diagnosis of premalignancy and malignancy and may have potential in classifying patients at risk for oral premalignant and malignant lesions in settings without access to a skilled dental practitioner. This may also potentially identify patients with premalignant and malignant lesions that do not meet the criteria for high clinical risk based on skilled dental examination.
Pattani
Kavita Malhotra
KM
Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins Medical Institutions, 601 North Caroline Street, 6th Floor, Baltimore, MD 21287-0910, USA.
Zhang
Zhe
Z
Demokan
Semra
S
Glazer
Chad
C
Loyo
Myriam
M
Goodman
Steven
S
Sidransky
David
D
Bermudez
Francisco
F
Jean-Charles
Germain
G
McCaffrey
Thomas
T
Padhya
Tapan
T
Phelan
Joan
J
Spivakovsky
Silvia
S
Bowne
Helen Yoo
HY
Goldberg
Judith D
JD
Rolnitzky
Linda
L
Robbins
Miriam
M
Kerr
A Ross
AR
Sirois
David
D
Califano
Joseph A
JA
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002294:Carcinoma, Squamous Cell / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D019175:DNA Methylation / Q000235:genetics; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D020022:Genetic Predisposition to Disease / Q000235:genetics; D006801:Humans; D016547:Kinesins / Q000235:genetics / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009055:Mouth / Q000378:metabolism / Q000473:pathology; D009062:Mouth Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D011230:Precancerous Conditions / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D011401:Promoter Regions, Genetic; D044023:Receptor, Endothelin B / Q000235:genetics* / Q000378:metabolism; D012307:Risk Factors; D012463:Saliva / Q000378:metabolism*; D055815:Young Adult
C094065:KIF1A protein, human; D044023:Receptor, Endothelin B; D016547:Kinesins
Urology. 2008 Jan;71(1):161-7
18242387
Oral Oncol. 2000 Nov;36(6):525-8
11036246
J Cancer Educ. 2004 Spring;19(1):12-6
15059751
Clin Cancer Res. 2008 Jan 1;14(1):97-107
18172258
Nat Med. 1995 Jul;1(7):686-92
7585152
Chin J Physiol. 2008 Feb 29;51(1):27-31
18551992
Cancer Res. 2003 Aug 1;63(15):4620-5
12907641
Prostate. 2004 Jun 15;60(1):25-31
15129426
Int J Oral Maxillofac Surg. 2002 Jun;31(3):262-6
12190131
Cancer Res. 2004 Mar 15;64(6):1975-86
15026333
Oncol Rep. 2006 Feb;15(2):507-11
16391877
Cancer Res. 1996 Feb 15;56(4):722-7
8631003
Oncol Rep. 2006 Jan;15(1):167-72
16328051
Eur Urol. 2007 Mar;51(3):665-74; discussion 674
16956712
Dis Esophagus. 2009;22(1):55-61
18564167
J Urol. 2008 Feb;179(2):529-34; discussion 534-5
18076941
Curr Oncol Rep. 2005 Mar;7(2):145-53
15717949
Int J Cancer. 2010 Nov 15;127(10):2351-9
20162572
Cancer Res. 2001 Feb 1;61(3):939-42
11221887
Clin Cancer Res. 2003 Apr;9(4):1370-5
12684406
BMC Cancer. 2009 Oct 18;9:370
19835631
Health Technol Assess. 2006 Apr;10(14):1-144, iii-iv
16707071
Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6
8790415
Int J Cancer. 2002 Apr 10;98(5):651-5
11920632
Clin Cancer Res. 2009 Feb 15;15(4):1184-91
19228724
Community Dent Oral Epidemiol. 1980 Feb;8(1):1-26
6929240
Clin Cancer Res. 2007 Apr 1;13(7):2046-53
17404085
J Cancer Educ. 1998 Summer;13(2):90-5
9659627
J Mol Diagn. 2001 Nov;3(4):164-70
11687600
J Clin Pathol. 2003 Jan;56(1):52-5
12499435
Int J Cancer. 2005 Nov 20;117(4):605-10
15929076
Lancet Oncol. 2006 Jan;7(1):77-82
16389187
Cancer Res. 1997 Jan 1;57(1):35-7
8988036
Clin Cancer Res. 2004 Nov 15;10(22):7457-65
15569975
Oral Oncol. 2008 Jan;44(1):10-22
17825602